GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2007

Vical Receives Grant to Advance RapidResponse DNA Vaccine Platform

  • Vical reports that it was awarded a three-year, $6-million grant from the NIAID for further development of a DNA vaccine manufacturing process that has the the potential to produce several million doses of vaccines in a matter of days.

    “The standard manufacturing methods that are being used to produce conventional vaccines take several months to several years and require specialized, capital-intensive facilities,” explains Vijay Samant, president and CEO of Vical. “The RapidResponse™ system is designed to allow extremely rapid and large-scale production of DNA vaccines with low capital requirements. It is ideally suited to enable an immediate response against emerging diseases affecting large populations, such as a pandemic influenza or SARS.”

    According to Samant, the RapidResponse DNA vaccine manufacturing platform is intended to significantly reduce the time required to develop, manufacture, and deploy vaccines against emerging diseases during the early stages of an infectious outbreak. By using a cell-free manufacturing process, the company believes that the platform can overcome the time, capacity, and cost challenges of producing conventional vaccines for diseases such as influenza.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?